Search Result

Results for "

efficacy and safety profile

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (1) Akt (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Bacterial (1) Bcr-Abl (1) Drug Derivative (1) Elastase (1) Glutathione S-transferase (1) HBV (1) Insecticide (1) Keap1-Nrf2 (2) P2Y Receptor (1) PD-1/PD-L1 (1) PROTACs (1) Proteasome (1) Reference Standards (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (5) Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-177439

HLX43	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .

HY-100375

Diroximel fumarate 4 Publications Verification ALKS 8700; BIIB098	Keap1-Nrf2	Inflammation/Immunology
Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS). Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity .

HY-179537

CKBA	Acetyl-CoA Carboxylase Drug Derivative	Inflammation/Immunology
CKBA, a derivative of AKBA (HY-N0892) is an inhibitor of acetyl-CoA carboxylase 1 (ACC1), with an IC₅₀ of 5.02 μM. CKBA inhibits the differentiation of Th17 cells and has IC₅₀ values of 3.28 μM for mouse cells and 3.61 μM for human cells. CKBA ointment significantly alleviates psoriasis-like inflammation in mice. CKBA can be used for the study of psoriasis .

HY-178175

Chitin synthase-IN-15	Insecticide	Infection
Chitin synthase-IN-15 (Compound 6k) is a chitin synthase inhibitor. Chitin synthase-IN-15 has insecticidal efficacy against Plutella xylostella, with LC₅₀ values of 0.789 and 0.951 μg/mL. Chitin synthase-IN-15 induces molting disruptions, larval mortality, and aberrant pupation, thereby effectively mitigating pest populations. Chitin synthase-IN-15 is an insecticidal agent with favorable ecological safety profiles .

HY-111755

P2Y12 antagonist 2	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 2 is a potent P2Y₁₂ receptor antagonist. P2Y12 antagonist 2 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. P2Y12 antagonist 2 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. P2Y12 antagonist 2 can be used to research thromboembolic disorders .

HY-179389

XDS-23	Bacterial Glutathione S-transferase Elastase	Infection
XDS-23 is a selective biofilm inhibitor with an IC₅₀ of 1.26 µM against Pseudomonas aeruginosa. XDS-23 exerts a dual inhibitory effect on the LasI/LasR System (las) and Pseudomonas Quinolone Signal System (pqs). XDS-23 suppress the production of key virulence factors including elastase, pyocyanin, and extracellular polysaccharides. XDS-23 exhibits synergistic antibacterial activity and can enhance the efficacy of multiple antibiotics in both in vitro and in vivo models, while maintaining a favorable safety profile. XDS-23 can be employed for research in combating biofilm-mediated drug-resistant P. aeruginosa infections .

HY-16469

SR 13668	Akt	Cancer
SR13668 is a potent indole analog derived from indole-3-carbinol (I3C), known for its natural anticancer properties but limited by poor metabolic characteristics. Developed to enhance I3C's anticancer efficacy, SR13668 effectively inhibits growth factor-stimulated Akt activation. It demonstrates strong oral anticancer activity across different cancer types in preclinical studies, showing promise in clinical development due to its favorable safety profile and potent therapeutic effects .

HY-180186

Xanthine oxidase-IN-20	Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor with an IC₅₀ of 1.7 nM. Xanthine oxidase-IN-20 exhibits outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Xanthine oxidase-IN-20 shows favorable safety profile. Xanthine oxidase-IN-20 can be used for hyperuricemia and gout research .

HY-100375R

Diroximel fumarate (Standard) ALKS 8700 (Standard); BIIB098 (Standard)	Reference Standards Keap1-Nrf2	Inflammation/Immunology
Diroximel fumarate (Standard) is the analytical standard of Diroximel fumarate (HY-100375). This product is intended for research and analytical applications. Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS). Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity .

HY-179394

Immunoproteasome-IN-2	Proteasome	Inflammation/Immunology
Immunoproteasome-IN-2 is selective immunoproteasome inhibitor with IC₅₀ = 232.3 nM for LMP7, IC₅₀ = 9384.9 nM for β5. Immunoproteasome-IN-2 exhibits ancillary inhibitory activity against LMP2 and MECL-1 subunits. Immunoproteasome-IN-2 demonstrates anti-inflammatory efficacy in a mouse model of arthritis and shows a favorable safety profile in toxicological studies with reduced hepatotoxicity and hematotoxicity. Immunoproteasome-IN-2 has LMP7/β5 selectivity directly correlated with lower systemic toxicity. Immunoproteasome-IN-2 can be employed for research in arthritis .

HY-180967

PROTAC BCR-ABL Degrader-2	Bcr-Abl PROTACs Apoptosis	Cancer
PROTAC BCR-ABL Degrader-2 is a selective Bcr-Abl ^T315 PROTAC degrader with a DC₅₀ of 108.7 nM in Ba/F3 Bcr-Abl ^T315I cells. PROTAC BCR-ABL Degrader-2 exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nM, respectively. PROTAC BCR-ABL Degrader-2 demonstrates high plasma exposure, and induces significant tumor regression and induces tumor cell apoptosis with a good safety profile in vivo. PROTAC BCR-ABL Degrader-2 can be used for chronic myeloid leukemia (CML) research .

HY-180524

CAB7-3	HBV	Infection
CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC₅₀ = 70 nM, CC₅₀ = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC₅₀ = 70 nM), HepAD38 (EC₅₀ = 1 nM) and HBV-infected HLCZ01 cells (EC₅₀ = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research .

Cat. No.	Product Name

HY-L929

Fragment Library with Good Solubility	2,527 compounds
In drug discovery and development (R&D) area, target binding and druggability optimization are core processes. Among these attributes, high solubility is critical for a compound to achieve druggability, as it directly impacts the progress of drug R&D. Superior solubility ensures the rapid dissolution and uniform distribution of drug molecules in vivo, thereby enhancing bioavailability and effectively mitigating issues such as suboptimal efficacy, increased dosage requirements, or exacerbated toxic and side effects arising from insufficient solubility. From the perspective of medicinal chemistry, high-solubility drug fragments serve as high-quality "molecular building blocks". Based on these fragments, lead compounds with potential druggability can be rapidly screened out, which significantly shortens the drug R&D cycle and reduces R&D costs. Meanwhile, the high-solubility drug fragment library can provide diverse options for drug development in different therapeutic areas, offer solutions for the solubility defects of existing clinical drugs, and facilitate the development of novel, highly effective targeted drugs with higher bioavailability and better safety profiles. MCE has collected and compiled 2,527 experimentally validated small-molecule fragments with high solubility. These fragments can be directly used for drug molecular design, providing high-quality pre-validated solubility fragments that significantly improve the efficiency of lead compound screening and accelerate the progress of drug R&D.

Fragment Library with Good Solubility

2,527 compounds

In drug discovery and development (R&D) area, target binding and druggability optimization are core processes. Among these attributes, high solubility is critical for a compound to achieve druggability, as it directly impacts the progress of drug R&D. Superior solubility ensures the rapid dissolution and uniform distribution of drug molecules in vivo, thereby enhancing bioavailability and effectively mitigating issues such as suboptimal efficacy, increased dosage requirements, or exacerbated toxic and side effects arising from insufficient solubility.

From the perspective of medicinal chemistry, high-solubility drug fragments serve as high-quality "molecular building blocks". Based on these fragments, lead compounds with potential druggability can be rapidly screened out, which significantly shortens the drug R&D cycle and reduces R&D costs. Meanwhile, the high-solubility drug fragment library can provide diverse options for drug development in different therapeutic areas, offer solutions for the solubility defects of existing clinical drugs, and facilitate the development of novel, highly effective targeted drugs with higher bioavailability and better safety profiles.

MCE has collected and compiled 2,527 experimentally validated small-molecule fragments with high solubility. These fragments can be directly used for drug molecular design, providing high-quality pre-validated solubility fragments that significantly improve the efficiency of lead compound screening and accelerate the progress of drug R&D.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.